Paget-Schroetter disease medical therapy: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 10: Line 10:


*  
*  
* Considering more belligerent treatment method cite greater outcomes with lower rate of recurrent thrombus.<ref name="RinghouseJackson20173">{{cite journal|last1=Ringhouse|first1=Brendan|last2=Jackson|first2=Cody|title=Bringing to Light Symptoms and Treatments of Effort Thrombosis (Paget–Schroetter Syndrome) in the Military Population, a Case Study|journal=Military Medicine|volume=182|issue=5|year=2017|pages=e1826–e1829|issn=0026-4075|doi=10.7205/MILMED-D-16-00359}}</ref>
* Considering more belligerent treatment method cite greater outcomes with lower rate of recurrent [[thrombus]].<ref name="RinghouseJackson20173">{{cite journal|last1=Ringhouse|first1=Brendan|last2=Jackson|first2=Cody|title=Bringing to Light Symptoms and Treatments of Effort Thrombosis (Paget–Schroetter Syndrome) in the Military Population, a Case Study|journal=Military Medicine|volume=182|issue=5|year=2017|pages=e1826–e1829|issn=0026-4075|doi=10.7205/MILMED-D-16-00359}}</ref>
* Systemic fibrinolysis:
* Systemic [[fibrinolysis]]:
** More efficient than anticoagulation therapy<ref name="pmid21079709">{{cite journal| author=Alla VM, Natarajan N, Kaushik M, Warrier R, Nair CK| title=Paget-schroetter syndrome: review of pathogenesis and treatment of effort thrombosis. | journal=West J Emerg Med | year= 2010 | volume= 11 | issue= 4 | pages= 358-62 | pmid=21079709 | doi= | pmc=2967689 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21079709  }}</ref>
** More efficient than [[Anticoagulant|anticoagulation]] therapy<ref name="pmid21079709">{{cite journal| author=Alla VM, Natarajan N, Kaushik M, Warrier R, Nair CK| title=Paget-schroetter syndrome: review of pathogenesis and treatment of effort thrombosis. | journal=West J Emerg Med | year= 2010 | volume= 11 | issue= 4 | pages= 358-62 | pmid=21079709 | doi= | pmc=2967689 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21079709  }}</ref>
** Higher chance of developing worrisome complications like intracranial hemorrhage compared to anticoagulation therapy<ref name="pmid210797094">{{cite journal| author=Alla VM, Natarajan N, Kaushik M, Warrier R, Nair CK| title=Paget-schroetter syndrome: review of pathogenesis and treatment of effort thrombosis. | journal=West J Emerg Med | year= 2010 | volume= 11 | issue= 4 | pages= 358-62 | pmid=21079709 | doi= | pmc=2967689 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21079709  }}</ref>
** Higher chance of developing worrisome complications like [[intracranial hemorrhage]] compared to [[Anticoagulant|anticoagulation therapy]]<ref name="pmid210797094">{{cite journal| author=Alla VM, Natarajan N, Kaushik M, Warrier R, Nair CK| title=Paget-schroetter syndrome: review of pathogenesis and treatment of effort thrombosis. | journal=West J Emerg Med | year= 2010 | volume= 11 | issue= 4 | pages= 358-62 | pmid=21079709 | doi= | pmc=2967689 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21079709  }}</ref>


* Local catheter-directed thrombolysis:  
* Local [[catheter]]-directed [[thrombolysis]]:  
** Recommended in all early presenting patients based on some studies<ref name="pmid210797095">{{cite journal| author=Alla VM, Natarajan N, Kaushik M, Warrier R, Nair CK| title=Paget-schroetter syndrome: review of pathogenesis and treatment of effort thrombosis. | journal=West J Emerg Med | year= 2010 | volume= 11 | issue= 4 | pages= 358-62 | pmid=21079709 | doi= | pmc=2967689 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21079709  }}</ref>, while others suggest this method for sever cases, large thrombosis, low risk of bleeding, patients with good general health condition and life expectancy more than a year.<ref name="RinghouseJackson20172">{{cite journal|last1=Ringhouse|first1=Brendan|last2=Jackson|first2=Cody|title=Bringing to Light Symptoms and Treatments of Effort Thrombosis (Paget–Schroetter Syndrome) in the Military Population, a Case Study|journal=Military Medicine|volume=182|issue=5|year=2017|pages=e1826–e1829|issn=0026-4075|doi=10.7205/MILMED-D-16-00359}}</ref>
** Recommended in all early presenting patients based on some studies<ref name="pmid210797095">{{cite journal| author=Alla VM, Natarajan N, Kaushik M, Warrier R, Nair CK| title=Paget-schroetter syndrome: review of pathogenesis and treatment of effort thrombosis. | journal=West J Emerg Med | year= 2010 | volume= 11 | issue= 4 | pages= 358-62 | pmid=21079709 | doi= | pmc=2967689 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21079709  }}</ref>, while others suggest this method for sever cases, large [[thrombosis]], low risk of [[bleeding]], patients with good general health condition and [[life expectancy]] more than a year.<ref name="RinghouseJackson20172">{{cite journal|last1=Ringhouse|first1=Brendan|last2=Jackson|first2=Cody|title=Bringing to Light Symptoms and Treatments of Effort Thrombosis (Paget–Schroetter Syndrome) in the Military Population, a Case Study|journal=Military Medicine|volume=182|issue=5|year=2017|pages=e1826–e1829|issn=0026-4075|doi=10.7205/MILMED-D-16-00359}}</ref>
** Studies have been demonstrated that there is an indirect relationship between efficacy of local thrombolytic therapy and duration between symptom onset to treatment. Therefore it is critical to diagnose and treat as soon as possible.<ref name="pmid210797097">{{cite journal| author=Alla VM, Natarajan N, Kaushik M, Warrier R, Nair CK| title=Paget-schroetter syndrome: review of pathogenesis and treatment of effort thrombosis. | journal=West J Emerg Med | year= 2010 | volume= 11 | issue= 4 | pages= 358-62 | pmid=21079709 | doi= | pmc=2967689 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21079709  }}</ref> Some studies suggest to consider local catheter-directed thrombolysis within the first 14 days of symptoms onset with success rate of 84%<ref name="RinghouseJackson2017">{{cite journal|last1=Ringhouse|first1=Brendan|last2=Jackson|first2=Cody|title=Bringing to Light Symptoms and Treatments of Effort Thrombosis (Paget–Schroetter Syndrome) in the Military Population, a Case Study|journal=Military Medicine|volume=182|issue=5|year=2017|pages=e1826–e1829|issn=0026-4075|doi=10.7205/MILMED-D-16-00359}}</ref>
** Studies have been demonstrated that there is an indirect relationship between efficacy of local [[Thrombolytic drug|thrombolytic therapy]] and duration between symptom onset to treatment. Therefore it is critical to diagnose and treat as soon as possible.<ref name="pmid210797097">{{cite journal| author=Alla VM, Natarajan N, Kaushik M, Warrier R, Nair CK| title=Paget-schroetter syndrome: review of pathogenesis and treatment of effort thrombosis. | journal=West J Emerg Med | year= 2010 | volume= 11 | issue= 4 | pages= 358-62 | pmid=21079709 | doi= | pmc=2967689 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21079709  }}</ref> Some studies suggest to consider local [[catheter]]-directed [[thrombolysis]] within the first 14 days of symptoms onset with success rate of 84%<ref name="RinghouseJackson2017">{{cite journal|last1=Ringhouse|first1=Brendan|last2=Jackson|first2=Cody|title=Bringing to Light Symptoms and Treatments of Effort Thrombosis (Paget–Schroetter Syndrome) in the Military Population, a Case Study|journal=Military Medicine|volume=182|issue=5|year=2017|pages=e1826–e1829|issn=0026-4075|doi=10.7205/MILMED-D-16-00359}}</ref>
** Same efficacy as systemic thrombolytic agents without any systemic side effects<ref name="pmid210797096">{{cite journal| author=Alla VM, Natarajan N, Kaushik M, Warrier R, Nair CK| title=Paget-schroetter syndrome: review of pathogenesis and treatment of effort thrombosis. | journal=West J Emerg Med | year= 2010 | volume= 11 | issue= 4 | pages= 358-62 | pmid=21079709 | doi= | pmc=2967689 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21079709  }}</ref>
** Same efficacy as systemic [[Thrombolytic drug|thrombolytic agents]] without any systemic [[Adverse effect (medicine)|side effects]]<ref name="pmid210797096">{{cite journal| author=Alla VM, Natarajan N, Kaushik M, Warrier R, Nair CK| title=Paget-schroetter syndrome: review of pathogenesis and treatment of effort thrombosis. | journal=West J Emerg Med | year= 2010 | volume= 11 | issue= 4 | pages= 358-62 | pmid=21079709 | doi= | pmc=2967689 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21079709  }}</ref>
** Newer agents like Alteplase and Reteplase are safer compared to urokinase or streptokinase <ref name="pmid210797093">{{cite journal| author=Alla VM, Natarajan N, Kaushik M, Warrier R, Nair CK| title=Paget-schroetter syndrome: review of pathogenesis and treatment of effort thrombosis. | journal=West J Emerg Med | year= 2010 | volume= 11 | issue= 4 | pages= 358-62 | pmid=21079709 | doi= | pmc=2967689 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21079709  }}</ref>
** Newer agents like [[Alteplase (injection)|Alteplase]] and [[Reteplase]] are safer compared to [[urokinase]] or [[streptokinase]] <ref name="pmid210797093">{{cite journal| author=Alla VM, Natarajan N, Kaushik M, Warrier R, Nair CK| title=Paget-schroetter syndrome: review of pathogenesis and treatment of effort thrombosis. | journal=West J Emerg Med | year= 2010 | volume= 11 | issue= 4 | pages= 358-62 | pmid=21079709 | doi= | pmc=2967689 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21079709  }}</ref>
** The average duration of thrombolytic infusion via catheter is estimated between 24-48 hours<ref name="pmid210797098">{{cite journal| author=Alla VM, Natarajan N, Kaushik M, Warrier R, Nair CK| title=Paget-schroetter syndrome: review of pathogenesis and treatment of effort thrombosis. | journal=West J Emerg Med | year= 2010 | volume= 11 | issue= 4 | pages= 358-62 | pmid=21079709 | doi= | pmc=2967689 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21079709  }}</ref>
** The average duration of [[Thrombolytic drug|thrombolytic]] infusion via [[catheter]] is estimated between 24-48 hours<ref name="pmid210797098">{{cite journal| author=Alla VM, Natarajan N, Kaushik M, Warrier R, Nair CK| title=Paget-schroetter syndrome: review of pathogenesis and treatment of effort thrombosis. | journal=West J Emerg Med | year= 2010 | volume= 11 | issue= 4 | pages= 358-62 | pmid=21079709 | doi= | pmc=2967689 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21079709  }}</ref>


==References==
==References==

Revision as of 20:56, 4 June 2020

Paget-Schroetter disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Paget-Schroetter disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Paget-Schroetter disease medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Paget-Schroetter disease medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Paget-Schroetter disease medical therapy

on Paget-Schroetter disease medical therapy

Paget-Schroetter disease medical therapy in the news

Blogs on Paget-Schroetter disease medical therapy

Directions to Hospitals Treating Paget-Schroetter disease

Risk calculators and risk factors for Paget-Schroetter disease medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview


Medical Therapy

References

  1. ↑ Ringhouse, Brendan; Jackson, Cody (2017). "Bringing to Light Symptoms and Treatments of Effort Thrombosis (Paget–Schroetter Syndrome) in the Military Population, a Case Study". Military Medicine. 182 (5): e1826–e1829. doi:10.7205/MILMED-D-16-00359. ISSN 0026-4075.
  2. ↑ Alla VM, Natarajan N, Kaushik M, Warrier R, Nair CK (2010). "Paget-schroetter syndrome: review of pathogenesis and treatment of effort thrombosis". West J Emerg Med. 11 (4): 358–62. PMC 2967689. PMID 21079709.
  3. ↑ Alla VM, Natarajan N, Kaushik M, Warrier R, Nair CK (2010). "Paget-schroetter syndrome: review of pathogenesis and treatment of effort thrombosis". West J Emerg Med. 11 (4): 358–62. PMC 2967689. PMID 21079709.
  4. ↑ Alla VM, Natarajan N, Kaushik M, Warrier R, Nair CK (2010). "Paget-schroetter syndrome: review of pathogenesis and treatment of effort thrombosis". West J Emerg Med. 11 (4): 358–62. PMC 2967689. PMID 21079709.
  5. ↑ Ringhouse, Brendan; Jackson, Cody (2017). "Bringing to Light Symptoms and Treatments of Effort Thrombosis (Paget–Schroetter Syndrome) in the Military Population, a Case Study". Military Medicine. 182 (5): e1826–e1829. doi:10.7205/MILMED-D-16-00359. ISSN 0026-4075.
  6. ↑ Alla VM, Natarajan N, Kaushik M, Warrier R, Nair CK (2010). "Paget-schroetter syndrome: review of pathogenesis and treatment of effort thrombosis". West J Emerg Med. 11 (4): 358–62. PMC 2967689. PMID 21079709.
  7. ↑ Ringhouse, Brendan; Jackson, Cody (2017). "Bringing to Light Symptoms and Treatments of Effort Thrombosis (Paget–Schroetter Syndrome) in the Military Population, a Case Study". Military Medicine. 182 (5): e1826–e1829. doi:10.7205/MILMED-D-16-00359. ISSN 0026-4075.
  8. ↑ Alla VM, Natarajan N, Kaushik M, Warrier R, Nair CK (2010). "Paget-schroetter syndrome: review of pathogenesis and treatment of effort thrombosis". West J Emerg Med. 11 (4): 358–62. PMC 2967689. PMID 21079709.
  9. ↑ Alla VM, Natarajan N, Kaushik M, Warrier R, Nair CK (2010). "Paget-schroetter syndrome: review of pathogenesis and treatment of effort thrombosis". West J Emerg Med. 11 (4): 358–62. PMC 2967689. PMID 21079709.
  10. ↑ Alla VM, Natarajan N, Kaushik M, Warrier R, Nair CK (2010). "Paget-schroetter syndrome: review of pathogenesis and treatment of effort thrombosis". West J Emerg Med. 11 (4): 358–62. PMC 2967689. PMID 21079709.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Paget-Schroetter_disease_medical_therapy&oldid=1610842"